Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Colorado Neurological Institute
mi
from
Englewood, CO
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Colorado Neurological Institute
mi
from
Englewood, CO
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
University of Connecticut Health Center
mi
from
Farmington, CT
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
University of Miami
mi
from
Miami, FL
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
University of Maryland School of Medicine
mi
from
Baltimore, MD
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Johns Hopkins University
mi
from
Baltimore, MD
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Massachusetts General Hospital - East
mi
from
Charlestown, MA
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Massachusetts General Hospital - East
mi
from
Charlestown, MA
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Struthers Parkinson's Center
mi
from
Golden Valley, MN
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Struthers Parkinson's Center
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Washington University
mi
from
St. Louis, MO
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Albany Medical College
mi
from
Albany, NY
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Albany Medical College
mi
from
Albany, NY
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Columbia University Medical Center
mi
from
New York, NY
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
University of Tennessee Health Science Center
mi
from
Memphis, TN
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
University of Tennessee Health Science Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated:  10/22/2012
Booth Gardner Parkinson's Care Center
mi
from
Kirkland, WA
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease
Status: Enrolling
Updated: 10/22/2012
Booth Gardner Parkinson's Care Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
Rancho Los Amigos National Rehabilitation Center
mi
from
Los Angeles (Downey), CA
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
Rancho Los Amigos National Rehabilitation Center
mi
from
Los Angeles (Downey), CA
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
UCLA/Orthopaedic Hospital Center for Cerebral Palsy
mi
from
Los Angeles, CA
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
UCLA/Orthopaedic Hospital Center for Cerebral Palsy
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
Kennedy Krieger Institute at Johns Hopkins University
mi
from
Baltimore, MD
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
Kennedy Krieger Institute at Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
Gillette Children's Specialty Healthcare
mi
from
St. Paul, MN
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
University Of Missouri-Columbia
mi
from
Columbia, MO
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
University Of Missouri-Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
Cleveland Clinic
mi
from
Cleveland, OH
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated:  10/25/2012
Swedish Medical Center
mi
from
Seattle, WA
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status: Enrolling
Updated: 10/25/2012
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
SynapDx Autism Gene Expression Analysis Study
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated:  10/29/2012
Children's Hospital - Boston
mi
from
Boston, MA
SynapDx Autism Gene Expression Analysis Study
SynapDx Autism Spectrum Disorder Gene Expression Analysis Study
Status: Enrolling
Updated: 10/29/2012
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Open-Trial of EPI-743 for Adults With Tourette Syndrome
Open-Trial of EPI-743 for Adults With Tourette Syndrome
Status: Enrolling
Updated:  10/29/2012
Yale Child Study Center
mi
from
New Haven, CT
Open-Trial of EPI-743 for Adults With Tourette Syndrome
Open-Trial of EPI-743 for Adults With Tourette Syndrome
Status: Enrolling
Updated: 10/29/2012
Yale Child Study Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
Status: Enrolling
Updated:  10/30/2012
Massachusetts General Hospital
mi
from
Boston, MA
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
Status: Enrolling
Updated: 10/30/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Zolpidem CR and Hospitalized Patients With Dementia
Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study
Status: Enrolling
Updated:  11/2/2012
Massachusetts General Hospital
mi
from
Boston, MA
Zolpidem CR and Hospitalized Patients With Dementia
Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study
Status: Enrolling
Updated: 11/2/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Alabaster, AL
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Alabaster, AL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Gilbert, AZ
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Fayetteville, AR
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Atlantis, FL
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Rochester, NY
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Asheville, NC
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated:  11/5/2012
Pfizer Investigational Site
mi
from
Houston, TX
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures
Status: Enrolling
Updated: 11/5/2012
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Harmonex Neuroscience Research
mi
from
Dothan, AL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Harmonex Neuroscience Research
mi
from
Dothan, AL
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Clinical Study Centers, LLC
mi
from
Little Rock, AR
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Clinical Study Centers, LLC
mi
from
Little Rock, AR
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Peninsula Research Associates
mi
from
Palos Verdes, CA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Peninsula Research Associates
mi
from
Palos Verdes, CA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Psychiatric Centers at San Diego (PCSD-Feighner Research Institute)
mi
from
San Diego, CA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Psychiatric Centers at San Diego (PCSD-Feighner Research Institute)
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Encompass Clinical Research
mi
from
Spring Valley, CA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Encompass Clinical Research
mi
from
Spring Valley, CA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Elite Clinical Trials
mi
from
Wildomar, CA
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Elite Clinical Trials
mi
from
Wildomar, CA
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
IMMUNO International Research Centers
mi
from
Centennial, CO
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
IMMUNO International Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Coastal Connecticut Research, LLC
mi
from
New London, CT
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Coastal Connecticut Research, LLC
mi
from
New London, CT
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Sarkis Clinical Trials
mi
from
Gainesville, FL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Amedica Research Institute, Inc.
mi
from
Hialeah, FL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Amedica Research Institute, Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
George M. Joseph, MD, PA
mi
from
Jacksonville Beach, FL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
George M. Joseph, MD, PA
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Morteza Nadjafi, MD, FAPA
mi
from
Orlando, FL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Morteza Nadjafi, MD, FAPA
mi
from
Orlando, FL
Click here to add this to my saved trials
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  11/5/2012
Miami Research Associates
mi
from
South Miami, FL
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 11/5/2012
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials